184 related articles for article (PubMed ID: 19446878)
21. [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
Zhong JS; Meng FY; Xu D; Dai M; Wei YQ; Zhou HS
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2120-3. PubMed ID: 22093988
[TBL] [Abstract][Full Text] [Related]
22. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
[TBL] [Abstract][Full Text] [Related]
24. The cytogenetic response as a surrogate marker of survival.
Rosti G; Testoni N; Martinelli G; Baccarani M
Semin Hematol; 2003 Apr; 40(2 Suppl 2):56-61. PubMed ID: 12783377
[TBL] [Abstract][Full Text] [Related]
25. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
[TBL] [Abstract][Full Text] [Related]
26. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Olavarria E; Ottmann OG; Deininger M; Clark RE; Bandini G; Byrne J; Lipton J; Vitek A; Michallet M; Siegert W; Ullmann A; Wassmann B; Niederwieser D; Fischer T;
Leukemia; 2003 Sep; 17(9):1707-12. PubMed ID: 12970768
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
Zou WY; Xu DR; Su C; Li J; Luo SK
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1660-2. PubMed ID: 18819894
[TBL] [Abstract][Full Text] [Related]
28. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
Breccia M; Diverio D; Pane F; Nanni M; Russo E; Biondo F; Frustaci A; Gentilini F; Alimena G
Leuk Res; 2006 Dec; 30(12):1577-9. PubMed ID: 16630657
[TBL] [Abstract][Full Text] [Related]
29. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
Faber E; Friedecký D; Mičová K; Rožmanová S; Divoká M; Jarošová M; Indrák K; Adam T
Ann Hematol; 2012 Jun; 91(6):923-9. PubMed ID: 22231281
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Bee PC; Gan GG; Teh A; Haris AR
Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
[TBL] [Abstract][Full Text] [Related]
31. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
Zaritskiĭ AIu; Lomaia EG; Vinogradova OIu; Druzhkova GA; Kolosheĭnova TI; Loria SS; Pospelova TI; Krylova IV; Kruglov SS; Kuznetsov SV; Chelysheva EIu; Abakumov EM; Sokolova MA; Nemchenko IS; Zakharova ES; Goriacheva SR; Kolosova LIu; Vakhrusheva MV; Liamkina AS; Chernova OA; Machiulaĭtene ER; Ivanova VL; Udal'eva VIu; Shneĭder TV; Ogorodnikova IuS; Zhuravlev VS; Zakharova AV; Martynkevich IS; Domracheva EV; Afanas'ev BV; Abdulkadyrov KM; Kovaleva LG; Khoroshko ND; Turkina AG
Ter Arkh; 2007; 79(8):17-22. PubMed ID: 17926465
[TBL] [Abstract][Full Text] [Related]
32. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
33. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M;
Cancer Genet Cytogenet; 2010 Jun; 199(2):76-80. PubMed ID: 20471509
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients.
Kobayashi S; Kimura F; Kobayashi A; Sato K; Motoyoshi K
Ann Hematol; 2009 Apr; 88(4):311-5. PubMed ID: 18704417
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
Clin Cancer Res; 2009 Feb; 15(3):1059-63. PubMed ID: 19188180
[TBL] [Abstract][Full Text] [Related]
36. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
Latagliata R; Breccia M; Carmosino I; Sarlo C; Montefusco E; Mancini M; Natalino F; Chistolini A; De Cuia R; Russo E; Morano GS; Biondo F; Spadea A; Mandelli F; Alimena G
Leuk Res; 2005 Mar; 29(3):287-91. PubMed ID: 15661264
[TBL] [Abstract][Full Text] [Related]
37. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
38. [Recovery of polyclonial hemopoiesis in females with chronic myeloid leukemia with a complete cytogenetic response].
Ermakova TA; Chelysheva EIu; Turkina AG; Sokolova MA; Zakharova AV; Danil'cheva ES; Misiurin AV
Ter Arkh; 2007; 79(8):13-6. PubMed ID: 17926464
[TBL] [Abstract][Full Text] [Related]
39. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
[TBL] [Abstract][Full Text] [Related]
40. Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
Oku E; Imamura R; Nagata S; Takata Y; Seki R; Otsubo K; Hashiguchi M; Osaki K; Yakushiji K; Yoshimoto K; Ogata H; Sata M; Okamura T
Acta Haematol; 2007; 117(4):191-6. PubMed ID: 17170522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]